# The endothelial plasma membrane lipidome and its remodeling under hyperglycemia: an exploratory study

**Authors:** Ana Reis, Yahya Sohrabi, Lorena Diaz-Sanchez, Ana Rita Dias Araújo, Merle Leffers, Bruno Antonny, Alisa Rudnitskaya, Rui Vitorino, Irundika H. K. Dias

PMC · DOI: 10.3389/fmolb.2025.1701375 · Frontiers in Molecular Biosciences · 2026-02-16

## TL;DR

This study explores how high blood sugar changes the lipid composition of endothelial cell membranes, which could impact vascular function and drug responses.

## Contribution

The study provides a detailed lipidomic profile of endothelial plasma membranes and their remodeling under hyperglycemia.

## Key findings

- Cholesterol constitutes nearly half of the endothelial membrane lipid composition.
- Hyperglycemia reduces phospholipid levels and increases membrane stiffness via a higher cholesterol-to-phospholipid ratio.
- Oxidized lipid profiles shift under hyperglycemia, suggesting altered lipid–protein interactions.

## Abstract

At the interface between blood and blood vessels, the endothelial plasma membrane is the first point of contact to external stimuli, triggering the cascade of intracellular events responsible for proper vascular function. However, the endothelial plasma membrane lipidome and its remodeling in pathological conditions remain largely unknown.

To address this gap, we present a comprehensive lipidomic analysis of cell-derived giant plasma membrane vesicles isolated from primary human umbilical vein endothelial cells cultured in vitro under normoglycemic conditions and their lipid remodeling in adaptation to hyperglycemia.

Using targeted mass spectrometry-based strategies, 251 lipids and 13 oxidized lipids from 20 subclasses were identified and quantified. Cholesterol accounted for almost half (45 mol%) of the membrane’s composition. In adaptation to hyperglycemia, the noticeable decrease in the total phospholipids extracted resulted in an increased cholesterol-to-phospholipid (Chol/PL) ratio, which is consistent with increased membrane stiffening. Several other lipid subclasses, namely, lysolipids, phosphatidylcholines, aminophospholipids, polyunsaturated sphingomyelins, and other polyunsaturated phospholipids, showed a decreasing trend. Oxysterols displayed a shift toward the predominance of enzymatic (tail-oxidized) in hyperglycemia, whereas truncated oxidized phosphatidylcholines (oxPC) with a terminal aldehyde moiety exhibited a decreasing trend, suggesting the formation of lipid–protein cross-linking modification.

The hyperglycemia-induced alterations provide insights into the endothelial membrane lipid environment and the biophysical dynamics that are likely to deregulate protein–lipid interactions involved in sugar and lipid metabolism. The high amount of Chol found in our work serves as the basis for future in silico simulations crucial for drug design and drug response evaluation.

## Linked entities

- **Species:** Homo sapiens (taxon 9606)

## Full-text entities

- **Genes:** CYP46A1 (cytochrome P450 family 46 subfamily A member 1) [NCBI Gene 10858] {aka CP46, CYP46}, CH25H (cholesterol 25-hydroxylase) [NCBI Gene 9023] {aka C25H}, CTSA (cathepsin A) [NCBI Gene 5476] {aka BSVD6, GLB2, GSL, NGBE, PPCA, PPGB}, LDLR (low density lipoprotein receptor) [NCBI Gene 3949] {aka LDLCQ2}, ICAM1 (intercellular adhesion molecule 1) [NCBI Gene 3383] {aka BB2, CD54, P3.58}, VIP (vasoactive intestinal peptide) [NCBI Gene 7432] {aka PHM27}, VCAM1 (vascular cell adhesion molecule 1) [NCBI Gene 7412] {aka CD106, INCAM-100}, CYP27A1 (cytochrome P450 family 27 subfamily A member 1) [NCBI Gene 1593] {aka CP27, CTX, CYP27}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, NOS3 (nitric oxide synthase 3) [NCBI Gene 4846] {aka EC-NOS, ECNOS, MYMY8, NOSIII, cNOS, eNOS}, SELE (selectin E) [NCBI Gene 6401] {aka CD62E, ELAM, ELAM1, ESEL, LECAM2, selectin-e}, SLC2A1 (solute carrier family 2 member 1) [NCBI Gene 6513] {aka CSE, DYT17, DYT18, DYT9, EIG12, GLUT}
- **Diseases:** hepatitis B. (MESH:D006509), endothelial dysfunction (MESH:D014652), diabetes (MESH:D003920), AD (MESH:D000544), SGPC (MESH:C536833), dyslipidemia (MESH:D050171), epithelial prostate cancer (MESH:D011471), hyperglycemia (MESH:D006943), inflammatory (MESH:D007249), complications (MESH:D008107), retinopathy (MESH:D058437), stroke (MESH:D020521), obesity (MESH:D009765), PC (MESH:C535298), atherogenic (MESH:D050197), hypertension (MESH:D006973), hyperglycemic (MESH:D006944), chronic diseases (MESH:D002908), neuropathy (MESH:D009422), PAzPC (MESH:C535589), heart disease (MESH:D006331), nephropathy (MESH:D007674), T2DM (MESH:D003924), HPTLC (MESH:D013851)
- **Chemicals:** streptomycin (MESH:D013307), carbon (MESH:D002244), Forssman glycolipids (MESH:C010163), dimethylamine (MESH:C034516), TG (MESH:D014280), (Glyco) sphingolipids (MESH:D006028), N2 (MESH:D009584), sugar (MESH:D000073893), formic acid (MESH:C030544), PI (MESH:D010716), P (MESH:D010758), 24(S)-hydroxycholesterol (MESH:C044563), glycerophospholipid (MESH:D020404), Methanol (MESH:D000432), PA (MESH:D011478), NaCl (MESH:D012965), 7-KC (MESH:C003001), hydroxyl (MESH:D017665), aldehyde (MESH:D000447), Cer (MESH:D002518), Chol (MESH:D002784), NO (MESH:D009569), isopropanol (MESH:D019840), SDS (MESH:D012967), Oxysterols (MESH:D000072376), CaCl2 (MESH:D002122), globosides (MESH:D005915), PG (MESH:D010715), BHT (MESH:D002084), Free fatty acids (MESH:D005230), LPE (MESH:C008301), Cardiolipin (MESH:D002308), 26-hydroxycholesterol (MESH:C007042), Phospholipid (MESH:D010743), H2O (MESH:D014867), PS (MESH:D010718), FA (MESH:D005227), sulfatides (MESH:D013433), PC (MESH:D010713), CE (MESH:D002788), CL (MESH:D002713), phosphoric acid (MESH:C030242), toluene (MESH:D014050), dihydroceramides (MESH:C109343), copper(II) sulfate pentahydrate (MESH:D019327), penicillin (MESH:D010406), HEPES (MESH:D006531), gangliosides (MESH:D005732), Hex (MESH:D006586), S. (MESH:D013455), PE (MESH:C483858), SM (MESH:D013109), ethyl acetate (MESH:C007650), GPMV (-), O2 (MESH:D013481), lactosylceramides (MESH:D007790), ice (MESH:D007053), argon (MESH:D001128), ROS (MESH:D017382), Sphingosine (MESH:D013110)
- **Species:** Canis lupus familiaris (dog, subspecies) [taxon 9615], Human immunodeficiency virus 1 (no rank) [taxon 11676], Homo sapiens (human, species) [taxon 9606]
- **Mutations:** C-6  C
- **Cell lines:** HUVEC — Homo sapiens (Human), Finite cell line (CVCL_2959), Madin- — Bos taurus (Bovine), Spontaneously immortalized cell line (CVCL_0421), MDCK — Canis lupus familiaris (Dog), Spontaneously immortalized cell line (CVCL_0422), PC-3 — Mus musculus (Mouse), Hybridoma (CVCL_C6V6)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12950756/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12950756/full.md

## References

101 references — full list in the complete paper: https://tomesphere.com/paper/PMC12950756/full.md

---
Source: https://tomesphere.com/paper/PMC12950756